Navigation Links
New Treatment Offers Hope for Beating Aggressive Cancers
Date:4/28/2008

NASHVILLE, Tenn., April 29 /PRNewswire/ -- With an 89% initial success rate in arresting or eradicating some of the most aggressive cancers, a Nashville-based treatment is being offered to the public for the first time. According to NeoPlas Innovation Director of Research Dr. Stephen Cantrell, gathering more data to validate effectiveness is imperative, but "early human results are quite exciting. This treatment has been effective for malignant melanoma, as well as pancreatic and some of the other worst-prognosis cancers."

The new protocol incorporates a unique combination of FDA-approved drugs already known to be safe, each used by millions of people for other applications. When administered alone, these drugs show some benefit against cancer, but not enough to make a difference for most patients. The combination of the medicines, however, allows lower, more tolerable dosages and provides effectiveness not seen in previous single-drug studies.

The NeoPlas treatment shows benefit in several aggressive malignancies because it disables certain abnormal cellular processes many of them share. Based on experience and relevant lab research to date, staff members expect the best results for melanoma, pancreatic cancer, colon cancer, renal (kidney) cancer, mesothelioma, and a group of sarcomas, including osteosarcoma, chondrosarcoma and malignant fibrous histiocytoma. Patients who have other cancers can be considered on a case-by-case basis, since many of them may benefit also. Having received previous cancer treatments does not make a patient ineligible.

The regimen's most notable side-effect is fatigue. Most patients never experience nausea, vomiting, hair loss, bone marrow or immune system suppression, or other side-effects commonly affiliated with chemotherapy or radiation. An experienced physician prescribes and monitors all treatment and maintains close communication with the patient's established oncologist.

NeoPlas Innovation serves patients living throughout the country. Since treatment takes place on an outpatient basis, most patients travel to Nashville about once every two months. Additionally, physicians usually can tell if the program is working within eight weeks and quickly enable patients to make their best healthcare decisions.

NeoPlas Innovation's web site, http://www.neoplas.org , provides complete information and an interactive screening tool for patients who are considering this treatment. The center can be reached by calling 615-371-8100 or e-mailing office@neoplas.org.


'/>"/>
SOURCE NeoPlas Innovation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Dental Convention to Highlight Latest Breakthroughs in Oral Health Treatments
2. Study shows false memories complicate end-of-life treatment decisions
3. HHS, Cleveland Clinic Collaborate to Advance Treatment for Neurological Disorders
4. Autistic mannerisms reduced by sensory treatment
5. Mutation database helps personalized treatment of lung cancer
6. UCB Launches CIMplicity(TM) Program to Enhance Treatment Support for Cimzia(R) (certolizumab pegol) Patients and Caregivers
7. ACTwatch, to Improve Malaria Treatment, to Be Launched on World Malaria Day
8. Study finds racial disparities in smoking cessation treatment
9. Varian Medical Systems Announces Record Demand for New RapidArc(TM) Radiotherapy Treatment Capability
10. Annual Trachoma Treatments May Be Unnecessary
11. Discovery to hasten new malaria treatments, vaccines for children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... FL (PRWEB) , ... March 23, 2017 , ... ... dietary supplements that help improve all aspects of people’s health and nutrition, announced ... for nutritional products. , Natural Subsistence develops nutritional supplements that help people ...
(Date:3/23/2017)... Richey, FL (PRWEB) , ... March 23, 2017 , ... ... announce that 2017 marks the 40th Anniversary of ABQAURP’s dedication to Health Care Quality ... honors those who have contributed not only to the association, but also to the ...
(Date:3/23/2017)... Falls Church, VA (PRWEB) , ... ... ... Device Clinical Evaluation Reports: Complying with European Guidelines and the New MEDDEV ... p.m. – 3:00 p.m. ET, http://www.fdanews.com/mdclineval                  , How will the ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... “Beyond and ... “Beyond and Back” is the creation of published author Bonetta Rose, a wife, mother ... our lives. , Published by Christian Faith Publishing, Bonetta Rose‘s new book presents actual ...
(Date:3/23/2017)... ... March 23, 2017 , ... “A Respectful Response To Atheist ... To Atheist Manifesto” is the creation of published author Richard Hostetter, a former ... years. He holds graduate degrees from Kent State University and the University of ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, ... English version of the Annual report for 2016 is now ... ... NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine. ... medicines that preserve mitochondrial integrity and function in areas of ...
(Date:3/22/2017)... 2017 Research and Markets has announced the ... Trends - Industry Forecast to 2025" report to their offering. ... The Global ... of around 10.9% over the next decade to reach approximately $38.27 ... market estimates and forecasts for all the given segments on global ...
(Date:3/22/2017)... YORK , March 22, 2017 ... industry, Chinese pharmaceutical packaging market size increased year ... 2010-2016. From 2017 to 2021, the market size ... and is expected to outnumber RMB140 billion in ... policy, the rapid development of biological agents and ...
Breaking Medicine Technology: